| Characteristics |
Cases
N=154(%) |
Wild type
GG
N=86(%) |
Heterozygous
GT
N=64(%) |
Homo mutant
TT
N=4(%) |
P-Value |
Age of Diagnosis
21-30
31-40
41-50
51-60
61-70 |
16(10%)
38(25%)
50(32%)
38(25%)
12(8%) |
6(38%)
20(53%)
32(64%)
22(58%)
6(50%) |
10(62%)
16(42%)
18(36%)
14(37%)
6(50%) |
0(0%)
2(5%)
0(0%)
2(5%)
0(0%) |
0.16
0.35
0.005
0.06
1.00 |
Body mass index(BMI) status
Normal weight >18.50 to <24.99
Overweight >25 to <29.99
Obese >30.00 |
30(19%)
40(26%)
84(55%) |
17(57%)
22(55%)
47(57%) |
13(43%)
18(45%)
33(33%) |
0(0%)
0(0%)
4(10%) |
0.14
0.37
0.03 |
Age at Menarche
11-12
13-14
15-16 |
52(34%)
84(54%)
18(12%) |
34(65%)
48(57%)
4(22%) |
16(31%)
36(43%)
12(67%) |
2(4%)
0(0%)
2(11%) |
0.0005
0.06
0.01 |
Menopausal Status
Post Menopausal
Pre Menopausal |
80(52%)
74(48%) |
48(60%)
38(51%) |
30(38%)
34(46%) |
2(2%)
2(3%) |
0.004
0.51 |
Estrogen Receptor status
ER+ /PR+
ER+/PR-
ER-/PR+
ER-/PR- |
48(31%)
10(7%)
6(4%)
90(58%) |
28(58%)
8(80%)
4(67%)
46(51%) |
20(42%)
2(20%)
2(33%)
40(44%) |
0(0%)
0(0%)
0(0%)
4(5%) |
0.10
0.01
0.25
0.37 |
Her2 status
Her2+
Her2- |
135(88%)
19(12%) |
78(58%)
8(42%) |
54(40%)
10(53%) |
3(2%)
1(5%) |
0.003
0.50 |
Chemotherapy
5FU,Adriamycin,Endoxane
Hormonal therapy
RD
No Data |
108(70%)
11(7%)
28(18%)
7(4%) |
62(57%)
6(55%)
16(57%)
2(29%) |
42(39%)
5(45%)
12(43%)
5(71%) |
4(4%)
0(0%)
0(0%)
0(0%) |
0.006
0.67
0.28
0.12 |
